Compare Inovio Pharmaceuticals Inc (INO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Prudential PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 257.1× Inovio Pharmaceuticals Inc's market cap, and Prudential PLC pays a 2.33% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Prudential PLC for 119 Days on average.
| INO | PUK | |
|---|---|---|
Market Cap | $112.19M | $28.84B |
Volume | 3,201,278 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $2.65 | $33.61 |
52-Week Low | $0.66 | $23.54 |
Typical Hold Time | 43 Days | 119 Days |
Enterprise Value | $83.51M | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
